Amir Tehrani
As Precision Biopsy announces successful Phase 1 clinical trials of its prostate cancer diagnosis technology, it also announces the appointment of Amir Tehrani as its new CEO.
Prior to the role, Tehrani served as CEO at Amaranth Medical.
“With over 20 years of experience in strategy, marketing, design and development for both Fortune 500 and start-up medical device companies, I am confident in Amir’s ability to lead Precision Biopsy to commercial success,” said Dr. Omar Amirana, Managing Director at Allied Minds, Precision’s parent body.